Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00175864
Status:
WITHDRAWN
Last Update Posted:
2012-03-20
First Post:
2005-09-09
Brief Title:
Open Label Study Everyone Who Participates Receives Drug to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
Open Label Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam Ucb 44212 at Individualized Doses up to a Maximum of 160mgDay in Refractory Epileptic Patients
Status:
WITHDRAWN
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a safety and efficacy study of add on therapy with seletracetam in patients experiencing refractory epilepsy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Not yet available | None | None | None |